Tian'an Pharmaceutical Co., Ltd.
TNPH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 1.43 | 2.51 | 1.73 |
| FCF Yield | -0.08% | -0.57% | -0.55% | -0.77% |
| EV / EBITDA | -2,989.88 | -231.72 | 13.21 | -110.45 |
| Quality | ||||
| ROIC | 77.39% | 133.55% | -8.81% | -63.23% |
| Gross Margin | 0.00% | 47.32% | 100.00% | 0.00% |
| Cash Conversion Ratio | 2.25 | 0.81 | 0.69 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | 75.58% | 7.25% | 46.46% | 66.69% |
| Safety | ||||
| Net Debt / EBITDA | -43.71 | -5.36 | 0.86 | -2.18 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 4.19 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 949.47 | 256.47 | 0.00 |